1. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384–92.
2. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71;510–5.
3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1–75.
4. Nehler MR, McDermott MM, Treat-Jacobson D, et al. Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med 2003;8:115–26.
5. Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord 2005;5:14.
6. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381–6.
7. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463–654.
8. Layden J, Michaels J, Bermingham S, et al. Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance. BMJ 2012;345:e4947.
9. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004;172:95–105.
10. Soer R, van der Schans CP, Groothoff JW, et al. Towards consensus in operational definitions in functional capacity evaluation: a Delphi Survey. J Occup Rehabil 2008;18:389–400.
11. McDermott MM. Functional impairment in peripheral artery disease and how to improve it in 2013. Curr Cardiol Rep 2013;15:347.
12. Labs KH, Dormandy JA, Jaeger KA, et al. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 1999;100:e75–81.
13. Hiatt WR, Goldstone J, Smith SC, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation 2008;118:2826–9.
14. Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. J Am Geriatr Soc 1998;46:706–11.
15. McDermott MM, Guralnik JM, Criqui MH, et al. Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease. Circulation 2014;130:61–8.
16. McDermott MM, Ades PA, Dyer A, et al. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg 2008;48:1231–7, 7.e1.
17. Tew G, Copeland R, Le Faucheur A, et al. Feasibility and validity of self-reported walking capacity in patients with intermittent claudication. J Vasc Surg 2013;57:1227–34.
18. Le Faucheur A, Abraham P, Jaquinandi V, et al. Measurement of walking distance and speed in patients with peripheral arterial disease: a novel method using a global positioning system. Circulation 2008;117:897–904.
19. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990;2:142–52.
20. Verspaget M, Nicolaï SP, Kruidenier LM, et al. Validation of the Dutch version of the Walking Impairment Questionnaire. Eur J Vasc Endovasc Surg 2009;37:56–61.
21. Yan BP, Lau JY, Yu CM, et al. Chinese translation and validation of the Walking Impairment Questionnaire in patients with peripheral artery disease. Vasc Med 2011;16:167–72.
22. Collins TC, Suarez-Almazor M, Petersen NJ, O'Malley KJ. A Spanish translation of the Walking Impairment Questionnaire was validated for patients with peripheral arterial disease. J Clin Epidemiol 2004;57:1305–15.
23. McDermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009;301:165–74.
24. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012;125:130–9.
25. Ouedraogo N, Chanut M, Aubourg M, et al. Development and evaluation of the Walking Estimated-Limitation Calculated by History questionnaire in patients with claudication. J Vasc Surg 2013;58:981–8.
26. Tew GA, Nawaz S, Humphreys L, et al. Validation of the English version of the Walking Estimated-Limitation Calculated by History (WELCH) questionnaire in patients with intermittent claudication. Vasc Med 2014;19:27–32.
27. Mahe G, Ouedraogo N, Vasseur M, et al. Limitations of self-reported estimates of functional capacity using the Walking Impairment Questionnaire. Eur J Vasc Endovasc Surg 2011;41:104–9.
28. Ouedraogo N, Mahe G, Marchand J, et al. Validation of a new simple questionnaire to "estimate ambulation capacity by history" (EACH) in patients with claudication. J Vasc Surg 2011;54:133–8.
29. Mays RJ, Casserly IP, Kohrt WM, et al. Assessment of functional status and quality of life in claudication. J Vasc Surg 2011;53:1410–21.
30. Wind J, Koelemay MJ. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. Eur J Vasc Endovasc Surg 2007;34:1–9.
31. Fakhry F, van de Luijtgaarden KM, Bax L, et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg 2012;56:1132–42.
32. Fokkenrood HJ, Bendermacher BL, Lauret GJ, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2013;8:CD005263.
33. Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2014;7:CD000990.
34. Gommans LN, Saarloos R, Schelting MR, et al. Editor's choice--The effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 2014;48:169–84.
35. Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation 2011;123:87–97.
36. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274:975–80.
37. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. Sports Med 2004;34:983–1003.
38. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized controlled trials: Walking versus alternative exercise prescription as treatment for intermittent claudication. Atherosclerosis 2011;218:1–12.
39. Lauret GJ, Fakhry F, Fokkenrood HJ, et al. Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev 2014;7:CD009638.
40. Zwierska I, Walker RD, Choksy SA, et al. Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a randomized controlled trial. J Vasc Surg 2005;42:1122–30.
41. Tew G, Nawaz S, Zwierska I, Saxton JM. Limb-specific and cross-transfer effects of arm-crank exercise training in patients with symptomatic peripheral arterial disease. Clin Sci (Lond) 2009;117:405–13.
42. Regensteiner JG. Exercise rehabilitation for the patient with intermittent claudication: a highly effective yet underutilized treatment. Curr Drug Targets Cardiovasc Haematol Disord 2004;4:233–9.
43. Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg 2012;44:569–75.
44. Popplewell MA, Bradbury AW. Why do health systems not fund supervised exercise programmes for intermittent claudication? Eur J Vasc Endovasc Surg. 2014 Aug 28. [Epub ahead of print]
45. Cunningham MA, Swanson V, O'Carroll RE, et al. Randomized clinical trial of a brief psychological intervention to increase walking in patients with intermittent claudication. Br J Surg 2012;99:49–56.
46. Michie S, Ashford S, Sniehotta FF, et al. A refined taxonomy of behaviour change techniques to help people change their physical activity and healthy eating behaviours: the CALO-RE taxonomy. Psychol Health 2011;26:1479–98.
47. Al-Jundi W, Madbak K, Beard JD, et al. Systematic review of home-based exercise programmes for individuals with intermittent claudication. Eur J Vasc Endovasc Surg 2013;46:690–706.
48. Egberg L, Andreassen S, Mattiasson AC. Experiences of living with intermittent claudication. J Vasc Nurs 2012;30:5–10.
49. McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 2013;310:57–65.
50. Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation 2011;123:491–8.
51. Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012;99:1630–8.
52. Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess 2011;15:1–210.
53. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20:900–6.
54. Hong H, Mackey WC. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Clin Ther 2014;36:1290–301.
55. Momsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009;38:463–74.
56. Shahin Y, Mazari F, Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011;9:209–13.
57. Hunter MR, Cahoon WD, Lowe DK. Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease. Ann Pharmacother 2013;47:1552–7.
58. Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013;309:453–60.
59. Kinlay S. Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease. Circulation 2013;127:1241–50.
60. Ahimastos AA, Pappas EP, Buttner PG, et al. A meta-analysis of the outcome of endovascular and noninvasive therapies in the treatment of intermittent claudication. J Vasc Surg 2011;54:1511–21.
61. Nordanstig J, Taft C, Hensäter M, et al. Improved quality of life after one year with an invasive versus a non-invasive treatment strategy in claudicants: one year results of the IRONIC Trial. Circulation 2014 Aug. [Epub ahead of print]
62. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg 2012;55:1346–54.
63. Fakhry F, Rouwet EV, den Hoed PT, et al. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg 2013;100:1164–71.
64. Fokkenrood HJ, Scheltinga MR, Koelemay MJ, et al. Significant savings with a stepped care model for treatment of patients with intermittent claudication. Eur J Vasc Endovasc Surg 2014;48:423–9.
65. Spronk S, Bosch JL, den Hoed PT, et al. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg 2008;48:1472–80.
66. Ameli FM, Stein M, Aro L, et al. End-to-end versus end-to-side proximal anastomosis in aortobifemoral bypass surgery: does it matter? Can J Surg 1991;34:243–6.
67. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001;12:23–31.
68. Delaney CL, Spark JI, Thomas J, et al. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. Atherosclerosis 2013;229:1–9.
69. Pittler MH, Ernst E. Complementary therapies for peripheral arterial disease: systematic review. Atherosclerosis 2005;181:1–7.
70. Nicolaï SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2009 (2):CD006888.
71. Morling JR, Maxwell H, Stewart M. Padma 28 for intermittent claudication. Cochrane Database Syst Rev 2013;7:CD007371.
72. Campbell A, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2013;7:CD003833.
73. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000;2:CD000987.
74. Jepson RG, Kleijnen J, Leng GC. Garlic for peripheral arterial occlusive disease. Cochrane Database Syst Rev 2013;4:CD000095.
75. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev 2002;4:CD002785.
76. Kakkos SK, Geroulakos G, Nicolaides AN. Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial. Eur J Vasc Endovasc Surg 2005;30:164–75.
77. Delis KT, Nicolaides AN. Effect of intermittent pneumatic compression of foot and calf on walking distance, hemodynamics, and quality of life in patients with arterial claudication: a prospective randomized controlled study with 1-year follow-up. Ann Surg 2005;241:431–41.
78. de Haro J, Acin F, Florez A, et al. A prospective randomized controlled study with intermittent mechanical compression of the calf in patients with claudication. J Vasc Surg 2010;51:857–62.
